Source: Medovex Corp.
Medovex Corp. (NASDAQ: MDVX),
a developer of medical technology products, announced today that it has
added orthopedic industry veteran Ron Lawson to its Board of Directors.
Ron Lawson's 35 plus years of experience in the orthopedic
industry include the role as Senior Vice President of Worldwide Sales
and Customer Service for Pfizer's Orthopedic Division, Howmedica (1996).
In 1998, he became part of the Stryker Corporation with Stryker's
acquisition of Howmedica. At Stryker, he served as Senior Vice President
of Sales, Marketing and Product Development. Mr. Lawson also played a
critical and insightful role in the successful integration of the two
companies. In 2000, he was asked to lead the revitalization of Stryker's
European business as President, EMEA. He shortly thereafter assumed the
role of leadership for all of Stryker's International distribution
businesses and was promoted to Group President, International in 2001.
In 2005, Stryker assigned global responsibility of their
orthopedic division to Mr. Lawson making him Group President for
International and Global Orthopedics. He then focused on strengthening
the Stryker Orthopedic business worldwide. Ron retired from Stryker at
the end of 2007.
Ron Lawson is currently a member of the Lawson Group where he
provides strategic consulting services specializing in orthopedic
medical technology. He previously served as Chairman of the Board of
IMDS, Corporation. He also served as a member of the Health Care
Advisory Board of Arsenal Capital Partners. He presently serves as a
Director of Plasmology 4, Corporation as well as a Director of DJO
Global, a Blackstone company.
Jarrett Gorlin, Medovex Corporation Chief Executive Officer,
stated, "Mr. Lawson is well regarded as one of the key leaders aided in
the development of the orthopedic industry. With the progress of our
flagship DenerveX™ Device and other opportunities currently under
review, his addition to our team is highly strategic. We look forward to
working with Ron and leveraging his relationships throughout the world.
I'd also like to say a special thank you to outgoing board member
Thomas Hills for all of his invaluable support over the last couple
years."
Ron Lawson added, "I am pleased to have the opportunity to
serve on the Board of Medovex Corporation at a time I believe to be an
inflection point for the Company. The company is now strategically
positioned to offer great value to both surgeons and patients dealing
with pain associated with the Facet Joint. I look forward to assisting
management in identifying and vetting other potentially complementary
additions to its portfolio of assets, as well as helping to further
strengthen the Company's relationships with surgeon opinion leaders
around the world."
The Company's patented DenerveX System is currently in the
final development stages. It is designed to provide longer lasting
relief of pain associated with the facet joint. Lower back pain is the
second most common cause of disability in the U.S. for adults. Studies
indicate that 10% of the U.S. adult population suffers from lower back
pain and 31% of those affected are attributed to facet joint pain.
The DenerveX System consists of the DenerveX device kit, a
single use device, and the DenerveX Pro-40 Power Generator. The DenerveX
system is designed to provide a minimally invasive treatment option
which combines two actions into one device. The combined procedure is
expected to provide a longer lasting solution and potential savings to
the health care system.
DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.
About Medovex
Medovex was formed to acquire and develop a diversified
portfolio of potentially ground breaking medical technology products.
Criteria for selection include those products with potential for
significant improvement in the quality of patient care combined with
cost effectiveness. The Company's first pipeline product, the DenerveX
device, is intended to provide long lasting relief from pain associated
with facet joint syndrome at significantly less cost than currently
available options. To learn more about Medovex Corp., visit www.medovex.com
No comments:
Post a Comment